Milestone Pharmaceuticals' CARDAMYST launch tests investor patience
Commercial execution underway but mounting losses weigh on pre-commercial company as $200M cash runway provides buffer into 2027
Milestone Pharmaceuticals reported a marginal earnings beat in its fourth quarter, but the narrowly better-than-expected results offer little comfort to investors watching the Canadian biotechnology company navigate the critical early stages of its first commercial product launch.
The company posted a loss of $0.16 per share for the quarter, slightly ahead of analyst expectations for a $0.167 loss, according to regulatory filings. However, for a pre-commercial company that has yet to generate product revenue, the EPS variance carries minimal significance for investors focused on execution milestones and cash burn rates.
The more consequential development is the launch of CARDAMYST (etripamil nasal spray), which became available through U.S. retail pharmacies on January 26, 2026. The drug represents the first FDA-approved self-administered treatment for paroxysmal supraventricular tachycardia (PSVT), a heart rhythm disorder affecting more than two million Americans, marking the first new treatment option in 30 years for the condition.
Milestone deployed its national sales force in mid-February, bringing the commercial infrastructure online within eight weeks of the drug's December 2025 regulatory approval. Chief Executive Officer Joseph Oliveto reported that initial engagement from healthcare providers and payers is tracking "on or exceeding pre-launch expectations," according to the earnings filing.
The commercial push comes at a cost. Milestone's commercial spending surged to $28.3 million in the fourth quarter, up from $11.0 million in the prior-year period, reflecting investments in sales force deployment, marketing, and market access initiatives. The accelerated spending contributed to a widened full-year net loss of $0.75 per share, compared with $0.67 in fiscal 2024.
Despite the mounting losses, Milestone maintains a substantial financial cushion. The company holds approximately $200 million in pro forma cash, bolstered by a $75 million payment from rights partner RTW and $19 million raised through an at-the-market equity offering. Management projects this capital position will provide runway into late 2027, allowing sufficient time to demonstrate commercial traction and generate meaningful prescription data.
Investors have adopted a cautious stance on the launch prospects. Milestone shares have traded under pressure in recent weeks, declining 3.93% on March 12 and an additional 2.86% on March 16, according to market data. The stock closed at $1.70 on March 13, giving the company a market capitalization of approximately $145 million—well below the $8 average price target maintained by analysts, who rate the stock a moderate buy.
The company's strategy centers on demonstrating prescription volume through upcoming quarterly reports while simultaneously expanding the product's addressable market. Milestone is actively negotiating with insurers to secure formulary placement and has launched a patient assistance program that includes benefits verification and a $25 copay cap for eligible commercially insured patients, aiming to reduce financial and administrative barriers to adoption.
European expansion could provide an additional growth catalyst. The European Medicines Agency has accepted Milestone's marketing authorization application for etripamil nasal spray, which would be branded as TACHYMIST in European markets. A regulatory decision is expected in the first half of 2027.
Investors will receive additional data on CARDAMYST's clinical profile at the American College of Cardiology Annual Scientific Session later this month, where Milestone plans to present safety data demonstrating minimal blood pressure effects from the treatment. The presentation runs from March 28-30 and could provide further support for the drug's commercial positioning.
For now, Milestone remains in the proving ground phase common to biotechnology companies transitioning from research organizations to commercial enterprises. The company's $200 million cash position provides the luxury of time, but investors will expect to see prescription data in coming quarters that validates the positive initial feedback from healthcare providers and justifies the accelerated commercial spending. The launch execution over the next six months will likely determine whether Milestone can bridge the significant valuation gap between its current trading price and analyst targets, or whether the company will need to return to capital markets to fund its commercial ambitions.